| 1          | The impact of Mendelian sleep and circadian genetic variants in a population   |
|------------|--|
| 2          | setting  |
| 3          |  |
| 4          | Michael N. Weedon', PhD; Samuel E. Jones', PhD; Jacqueline. M. Lane <sup>3,4,3</sup> , PhD;  |
| 5          | Jiwon Lee <sup>o</sup> , PhD; Hanna M. Ollila <sup>2,7,9,8</sup> , PhD; Amy Dawes', BSc; Jess Tyrrell', PhD;                           |
| 6          | Robin N. Beaumont', PhD; Timo Partonen'', PhD; Ilona Merikanto''', PhD;  |
| 7          | Stephen S. Rich' <sup>2</sup> , PhD; Jerome I. Rotter <sup>19,17</sup> , MD; Timothy M. Frayling <sup>1</sup> , PhD; Martin            |
| 8          | K Rutter <sup>10,10</sup> , MD; Susan Redline <sup>o</sup> , PhD; Tamar Sofer <sup>o</sup> , PhD; Richa Saxena <sup>0,4,0</sup> , PhD; |
| 9          | Andrew R. Wood', PhD.  |
| 10         | 1 Constinue of Complex Traits, College of Medicine and Health, University of   |
| 11         | T. Genetics of Complex Trails, College of Medicine and Health, University of Exeter, Exeter, Deven, LIK                                |
| 12         | 2 Institute for Molecular Medicine Finland (FIMM) Hill IEE University of   |
| 13         | 2. Institute for Molecular Medicine Finland (Fimmi), Fildre, Oniversity of Holeinki, Holeinki, Einland                                 |
| 14<br>15   | Center for Cenomic Medicine, Massachusetts Ceneral Hospital and Harvard  |
| 16         | Medical School Boston MA USA   |
| 17         | 4 Broad Institute Cambridge MA USA   |
| 18         | 5. Department of Anesthesia. Critical Care and Pain Medicine. Massachusetts  |
| 19         | General Hospital, Boston, MA, USA.   |
| 20         | 6. Division of Sleep and Circadian Disorders. Brigham and Women's Hospital.  |
| 21         | Harvard Medical School, Boston, MA, USA.   |
| 22         | 7. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA,  |
| 23         | USA.   |
| 24         | 8. Program in Medical and Population Genetics, Broad Institute, Cambridge, MA,   |
| 25         | USA.   |
| 26         | <ol><li>Department of Psychiatry and Behavioral Sciences, School of Medicine,</li></ol>  |
| 27         | Stanford University, Stanford, CA, USA.  |
| 28         | 10. Department of Public Health Solutions, Finnish Institute for Health and  |
| 29         | Welfare, Helsinki, Finland.  |
| 30         | 11. SleepWell Research Program Unit, Faculty of Medicine, University of Helsinki,  |
| 31         | Helsinki, Finland.   |
| 32         | 12. Center for Public Health Genomics, Department of Public Health Sciences,   |
| 33         | University of Virginia, Charlottesville, VA, USA.  |
| 34<br>25   | 13. Institute for Genomics and Population Sciences, The Lundquist Institute for  |
| 35         | Biomedical Innovation, Torrance, CA, USA.  |
| 30<br>27   | 14. Department of Pediatrics, Harbor-OCLA Medical Center, Torrance, CA, USA.   |
| 38         | Medicine Biology and Health University of Manchester Manchester M13  |
| 30         |  |
| <i>4</i> 0 | 16 Diabetes Endocrinology and Metabolism Centre, Manchester University NHS   |
| 40         | Foundation Trust Manchester Academic Health Science Centre, Peter Mount  |
| 42         | Building 136 Hathersage Road Manchester M13 0HY UK   |
| 43         |  |
| 44         |  |
| 45         | Corresponding authors:   |
| 46         |  |
| 47         | Michael N Weedon   |
| 48         | Genetics of Complex Traits   |
| 49         | College of Medicine and Health   |

- 50 Medical Research Level 3 RILD Building
- 51 Royal Devon & Exeter Hospital
- 52 Barrack Road
- 53 Exeter EX2 5DW
- 54 Email: M.N.Weedon@exeter.ac.uk
- 55 Tel: +44 1392 408176
- 56
- 57 Andrew R Wood
- 58 Genetics of Complex Traits
- 59 College of Medicine and Health
- 60 Medical Research Level 3 RILD Building
- 61 Royal Devon & Exeter Hospital
- 62 Barrack Road
- 63 Exeter EX2 5DW
- 64 Email: A.R.Wood@exeter.ac.uk
- 65 Tel: +44 1392 408241
- 66
- 67 Manuscript word count: 4,136
- 68

### 69 **ABSTRACT**

70

71 Rare variants in ten genes have been reported to cause Mendelian sleep conditions 72 characterised by extreme sleep duration or timing. These include familial natural 73 short sleep (ADRB1, DEC2/BHLHE41, GRM1 and NPSR1), advanced sleep phase 74 (PER2, PER3, CRY2, CSNK1D and TIMELESS) and delayed sleep phase (CRY1). The association of variants of these genes with extreme sleep conditions were 75 usually based on clinically ascertained families, and their effects when identified in 76 77 the population are unknown. We aimed to determine the effects of these variants on 78 sleep traits in large population-based cohorts. 79 80 We performed genetic association analysis of variants previously reported to be causal for Mendelian sleep and circadian conditions. Analyses were performed using 81 82 191,929 individuals with data on sleep and whole-exome or genome-sequence data 83 from 4 population-based studies: UK Biobank, FINRISK, Health-2000-2001, and the 84 Multi-Ethnic Study of Atherosclerosis (MESA). We identified sleep disorders from 85 self-report, hospital and primary care data. We estimated sleep duration and timing 86 measures from self-report and accelerometery data. 87 88 We identified carriers for 10 out of 12 previously reported pathogenic variants for 8 of 89 the 10 genes. They ranged in frequency from 1 individual with the variant in 90 CSNK1D to 1,574 individuals with a reported variant in the PER3 gene in the UK 91 Biobank. We found no association of any of these variants with extreme sleep or 92 circadian phenotypes. Using sleep timing as a proxy measure for sleep phase, only 93 PER3 and CRY1 variants demonstrated association with earlier and later sleep 94 timing, respectively; however, the magnitude of effect was smaller than previously 95 reported (sleep midpoint ~7 mins earlier and ~5 mins later, respectively). We also 96 performed burden tests of protein truncating (PTVs) or rare missense variants for the 97 10 genes. Only PTVs in PER2 and PER3 were associated with a relevant trait (for example, 64 individuals with a PTV in PER2 had an odds ratio of 4.4 for being 98 "definitely a morning person",  $P=4x10^{-8}$ ; and had a 57-minute earlier midpoint sleep, 99  $P=5x10^{-7}$ ). 100 101

102 Our results indicate that previously reported variants for Mendelian sleep and

- 103 circadian conditions are often not highly penetrant when ascertained incidentally
- 104 from the general population.
- 105

#### 106 INTRODUCTION

107 108 Rare variants in ten genes have been reported to cause Mendelian sleep conditions 109 that are characterised by extreme sleep duration or timing. For example, variants in 110 the ADRB1, NPSR1 and GRM1 genes have been recently reported to cause familial 111 natural short sleep among carriers, defined as 4 to 6 hours sleep with no adverse effects on mental health or well-being<sup>1-3</sup>. Short sleep duration has also been reported 112 113 to be caused by variants in the DEC2/BHLHE41 gene, a well-known Mendelian 114 sleep gene<sup>4</sup>. Familial advanced sleep phase (FASP) where sleep timing is shifted 3 115 or 4 hours earlier has been reported for variants in PER2<sup>5</sup>, PER3<sup>6</sup>, CRY2<sup>7</sup>, CSNK1D<sup>8</sup> and TIMELESS<sup>9</sup>. The opposite condition, familial delayed sleep phase 116 117 disorder has been reported to be caused by a gain-of-function CRY1 variant, 118 c.1657+3A>C, with affected individuals sleeping approximately 1 hour later than unaffected individuals<sup>10</sup>. 119 120 121 The effect of variants in these genes on sleep duration and sleep timing when 122 identified incidentally in the general population is unknown. Discovery efforts for 123 these variants generally used either a single pedigree or a small number of families 124 selected on a specific clinical phenotype. For example, for ADRB1, six individuals in 125 a single family were affected with familial natural short sleep. This "phenotype first" 126 method of discovery means we do not know the effect of these variants when 127 identified in an individual from the general population (i.e. from a "genotype first" 128 approach). It is important to re-evaluate effect estimates to understand the 129 underlying biology which may inform clinical risk stratification, and because of the 130 recent dramatic increase in direct-to-consumer (DTC) and health service genome-131 wide genetic testing. To assess the effect of these variants when identified 132 incidentally, large, unselected population cohorts are needed. 133 134 Estimating the effects of these variants in the general population has not previously 135 been possible due to limitations in the availability of genetic data coupled with sleep 136 parameters. The UK Biobank, a population-based study of 500,000 individuals from 137 the UK, provides an opportunity to address questions of pathogenicity and penetrance of rare genetic conditions<sup>11</sup>. We have previously shown, for a range of 138 139 traits and diseases, that disease penetrance is generally lower in UK Biobank compared to that reported from clinical cohorts<sup>12,13</sup>. For example, using activity 140 141 monitor derived and self-report estimates of sleep timing from the UK Biobank, we 142 have demonstrated that the effect of the PER3 P415A/H417R familial advanced 143 sleep phase variant on sleep timing is substantially lower than the published estimate (0.13hrs vs. 4.2hrs)<sup>14</sup>. However, our previous studies were based on 144 145 genotyping array data of relatively common single nucleotide polymorphisms 146 (SNPs). Genotyping arrays are known to capture a relatively small number of rare 147 coding pathogenic disease variants, typically with poor accuracy for genotyping and imputation<sup>13,15,16</sup>. 148 149

- 150 In this study, we use exome sequencing data in up to 184,065 individuals of 151 European ancestry from the UK Biobank (October 2020 release) with sleep data,
  - 152 with additional data from up to 2,015 individuals from the Multi-Ethnic Study of
  - 153 Atherosclerosis (MESA), and 5,929 individuals from the FinnGen study to
  - 154 comprehensively assess the penetrance of Mendelian sleep and circadian genes in
  - 155 a population-based setting. We show that previously reported variants for Mendelian

156 sleep and circadian conditions are often not highly penetrant when identified

157 incidentally from the general population.

- 158
- 159

### 160 **METHODS**

161

## 162 UK Biobank Study Participants

The primary study population was drawn from the UK Biobank study – a longitudinal population-based study of individuals residing in the UK. We restricted our analysis

to a subset of 184,532 Europeans with whole-exome sequence data, including
 170,518 unrelated Europeans (<3<sup>rd</sup> degree) defined through kinship coefficients

- 167 made available from the UK Biobank. Details on derivation of genetic ancestry has
- 168 previously been reported in Jones *et al.*<sup>14</sup>.
- 169

# 170 Exome sequence data in UK Biobank

- 171 We used the second release of exome-sequence data from the UK Biobank
- 172 (October 2020). Specifically, we use genotypes called and provided in binary PLINK
- 173 format (data field: 23155). Genotypes for previously reported Mendelian causes of
- 174 sleep and circadian conditions were extracted for subsequent data analysis. Details
- of central processing of whole-exome data on 200K UK Biobank participants can be
- 176 found online as part of UK Biobank's data showcase:
- 177 <u>https://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=170.</u> All variants passed central
- quality control<sup>17</sup>. Sequence data for variants analysed in this paper were manually
  inspected through IGV<sup>18</sup> plots.
- 180
- 181 Sleep phenotypes and variant selection
- 182 We focussed our analysis on phenotypes previously reported to have Mendelian
- 183 causes, specifically familial natural short sleep ( $\leq 6$  hours)<sup>1,3,4</sup>, familial advanced
- 184 sleep phase characterised by earlier sleep onset and earlier waking<sup>5-9</sup>, and delayed
- 185 sleep phase disorder associated with later sleep onset and later waking<sup>10</sup>.
- 186
- 187 <u>Sleep disorders and medication</u>. We used data from the UK Biobank variable
- 188 131061 (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=131061) which
- 189 classifies individuals as having a sleep disorder based on self-report, hospital and
- 190 primary care data. As this variable does not separate out sub classifications of sleep
- 191 disorders we used ICD-10 codes G472 and F512 from in-patient data to specifically
- 192 assess disorders of the sleep wake cycle. Medication use at baseline in the UK
- 193 Biobank was identified from variable 20003
- 194 (<u>https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=20003</u>). Classification of sleep
- <sup>195</sup> medication used in this paper has previously been described<sup>19</sup>. Since 'sleep' is a
- 196 behavior, phenotyping is complicated. There are extreme sleep patterns like ASP
- and NSS which are often not considered 'disorders' by individuals if the trait does not
- <sup>198</sup> interfere with an individual's work and social demands<sup>20</sup>.
- 199
- 200 *Sleep Duration.* We used self-reported sleep duration from UK Biobank
- 201 questionnaire data (data field: 1160). We excluded individuals who reported >12
- 202 hours sleep duration, did not know or preferred not to answer. This data was also
- 203 dichotomized for multiple analyses to define "short sleepers" as individuals self-
- reporting sleep duration  $\leq$ 6 hours,  $\leq$ 5 hours,  $\leq$ 4 hours, and  $\geq$ 4 hours  $\leq$ 6. A maximum
- 205 of 166,360 individuals had genotype and self-report sleep duration available across

206 the variants previously reported to be Mendelian causes of familial natural short 207 sleep and prioritised for analysis. In addition, we used accelerometer estimates of nocturnal sleep derived in a previous study<sup>21</sup>. A maximum subset of 34,241 208 209 individuals remained for analysis of accelerometer-based sleep duration estimates 210 after removing individuals (n=4,323) with problematic accelerometer data processing 211 or who were outliers for the number of nocturnal sleep episodes used to derive nocturnal sleep estimates<sup>21</sup>. There was no association for individual variants or 212 213 overall with the individuals removed from the accelerometer analyses. We also 214 applied additional quality control among non-carriers of previously reported variants 215 described in this study by removing individuals with >12 hours estimated sleep 216 duration.

217

218 Sleep timing. We used self-reported diurnal preference available in the UK Biobank 219 (data field: 1180) as a proxy for sleep timing, whereby we assumed morning people 220 to sleep earlier and evening people to sleep later. We created four binary variables 221 to represent diurnal preference where individuals were coded '1' based on being: 1) 222 definitely a morning person; 2) more or definitely a morning person; 3) definitely an 223 evening person, and 4) more or definitely an evening person. For each variable, 224 individuals who did not report having the respective circadian preference(s) 225 (including "Do not know" but excluding "Prefer not to answer") were coded '0'. A 226 maximum of 168,409 individuals had genotype data and self-report chronotype data 227 across the variants associated with advanced and delayed sleep phase. In addition, 228 we used accelerometer estimates from up to 7 nights of the least-active 5 hours (L5) 229 over a 24-hour period, with values representing hours from the previous midnight (e.g.  $7 \square p.m. \square = \square 19$  and  $2 \square a.m. \square = \square 26)^{21}$ . Sleep midpoint was estimated as the mid-230 231 point of the sleep period time window used to define sleep duration<sup>21</sup>. In total, a 232 maximum subset of 34,650 individuals remained for statistical analysis of 233 accelerometer-based sleep timing estimates. We applied additional quality control 234 among non-carriers of previously reported variants described by removing 235 individuals outside 4 standard deviations of the respective trait (midpoint sleep or L5 236 timing) analysed. 237

- 238 Replication of Findings
- 239 To replicate our UK Biobank observations of previously reported variant-phenotype
- 240 associations, we used self-reported measures of sleep duration and circadian
- 241 preference (chronotype) in up to 5,929 individuals from two population-based studies
- from Finland: FINRISK<sup>22</sup> and Health-2000-2011 242
- 243 (https://www.julkari.fi/handle/10024/130780), available through the FinnGen Project
- 244 (https://www.finngen.fi/en). In addition, we used accelerometer-based estimates of
- 245 sleep timing (sleep midpoint) in up to 1,935 individuals from the Multi-Ethnic Study of
- Atherosclerosis (MESA) Sleep Study<sup>23</sup> where sequence-based genotypes of 246
- 247 previously reported variants associated with sleep timing from its Exam 5 were
- available (see Supplementary Information for study descriptors). 248
- 249
- 250 Statistical Analysis
- 251 Defining genotype groups for comparison of sleep parameter estimates. For each
- 252 variant, summaries of sleep parameter estimates were analysed with by genotype.
- 253 The set of individuals classified as homozygous reference for all variants was the
- 254 same after removing individuals from this genotype group who were carriers for other
- 255 variants.

### 256

257 Analysis of self-report phenotypes. t-tests tests were performed to compare means 258 and standard deviations of the continuous self-report sleep duration variables across 259 genotype groups and carrier status, respectively. For dichotomized variables, 260 Fisher's exact tests were performed to compare proportions of individuals labelled as 261 short sleepers or had a defined circadian preference (above) across genotype 262 groups. Alternate homozygous counts were combined with heterozygous counts 263 when performing Fisher's exact test where applicable. In addition, logistic regression 264 was performed using UK Biobank data to obtain odds ratios, adjusting for age at 265 baseline (field 21003), sex (field 31), assessment centre (field 54), month when 266 attending the assessment centre (field 55), and 40 genetic principal components 267 (field 22009) available from the UK Biobank.

268

269 Accelerometer-derived phenotypes. t-tests were performed to compare means and 270 standard deviations of the accelerometer-based estimates of sleep duration, sleep-271 midpoint and L5 timing.

272

273 Burden testing of rare loss-of-function and missense variants in UK Biobank. Genetic 274 variants identified in the ten previously reported genes were annotated using the Ensembl Variant Effect Predictor (VEP)<sup>24</sup> and LOFTEE<sup>25</sup>. Variants with MAF<0.0001 275 276 and annotated as missense or loss-of-function with high confidence were analysed through burden testing as implemented in Regenie<sup>26</sup> that accounts for relatedness 277 278 among individuals analysed. We analysed up to 184,065 individuals of inferred 279 European genetic ancestry with available sleep and covariate data.

280

### 281

### 282 RESULTS

283

#### 284 Most reported Mendelian sleep variants are present in UK Biobank and are not 285 associated with sleep disorders

286 We assessed the frequencies of 12 variants in 10 genes that have been reported to 287 cause familial natural short sleep, familial advanced sleep phase, or delayed sleep 288 phase conditions (Table 1). All were present in the UK Biobank in unrelated 289 individuals of European ancestry except for the S662G variant in PER2 (not present 290 in gnomAD (version 2.1)) and the Y206H variant in NPSR1. In addition, we identified 291 carriers for previously reported variants in GRM1, BHLHE41/DEC2, CRY1, and 292 PER3 in the MESA and Finnish studies (Table 2). None of the variants were 293 associated with any self-report or clinically diagnosed sleep disorder in UK Biobank, 294 including the G472 or F512 ICD-10 code for disorders of the sleep wake cycle or 295 with sleep medication use (**Supplementary Table 1**). We noted in the FinnGen 296 study there was a nominal association with ICD10 code G472 (circadian rhythm 297 sleep disorders) for the CRY1 c.1657+3A>C variant (0.05% in controls vs. 0.29% in 298 cases, P=0.026), but this variant is 10-fold rarer in the Finnish population than in 299 non-Finnish Europeans and is imputed with a quality score of only 0.76. 300 301

ADRB1, GRM1, or DEC2/BHLHE41 pathogenic variants are not associated with self-302 reported short sleep duration in population-based cohorts

303 We identified 149 unrelated individuals from the UK Biobank with self-reported

- 304 measures of sleep duration and carrying a previously reported pathogenic variant for
- 305 natural short sleep in ADRB1 (A817V, n=69), DEC2/BHLHE41 (P384R, n=10), or

306 GRM1 (S458A, n=67; A889T, n=3). We found no evidence that these individuals 307 have short sleep durations in the UK Biobank (Table 3 and Supplementary Tables 308 2 and 3). For example, the 69 carriers of the *ADRB1* variant had a self-reported 309 average sleep duration of 7.1 hours (95% CI: 6.9, 7.3) compared to 7.2 hours (95% 310 CI: 7.19, 7.21) among non-variant carriers (t-test P=0.62). The proportion of ADRB1 311 variant carriers self-reporting  $\leq 6$  hours of sleep, 23.2%, was no different to the 312 proportion of people not carrying the variant, 23.7% (Fisher's exact P=1.00). Using a 313 fully adjusted logistic regression model gave similar results with an odds ratio of 0.98 314 (95% CI: 0.56–1.72; P=0.96) for sleeping less than 6 hours. We observed zero 315 carriers of the ADRB1 variant self-reporting a more extreme phenotype of  $\leq 4$  hours 316 of sleep. Similar observations were made for previously reported monogenic sleep 317 disruption variants in DEC2/BHLHE41 and GRM1. The 10 carriers of the P384R 318 variant in the DEC2/BHLHE41 gene had an average self-reported sleep duration of 319 7.3 hours compared to 7.2 hours among non-carriers (P=0.69), with 10% of carriers 320 reporting ≤6 hours sleep duration compared to 23.7% among non-carriers of 321 reported variants (P=0.47). Carriers for variants in the *GRM1* gene did not 322 significantly differ in sleep duration from non-carriers (S458A: 7.1 hours (carriers) vs 323 7.2 hours (non-carriers), P=0.81; A889T: 8 hours (carriers) vs 7.2 hours (non-324 carriers), P=0.18), or the number of individuals reporting sleep duration of  $\leq 6$  hours 325 (S458A: 28.4% (carriers) vs 23.7% (non-carriers), P=0.39; A889T: 0% (carriers) vs 326 23.8% (non-carriers), P=1.00). The null effect of the S458A variant in GRM1 was also 327 observed in FinnGen where 2 S458A carriers were identified and had no statistically 328 significant difference compared to non-carriers in average sleep duration (t-test 329 *P*=0.92) or proportion self-reporting  $\leq 6$  hours sleep (Fisher's exact *P*=1.00) (**Table** 330 3). 331 332 ADBR1, GRM1, or DEC2/BHLHE41 pathogenic variants are not associated with 333 accelerometer derived measures of sleep in population based cohorts 334 We confirmed the lack of association between previously identified pathogenic 335 variants and sleep duration using accelerometer estimates of sleep in a subset of 336 34.226 individuals from the UK Biobank. Fifteen ADRB1 variant carriers with 337 accelerometer-derived sleep estimates had an average sleep duration of 7.6 hours 338 (95% CI: 7.4, 7.8) compared to 7.3 hours (95% CI: 7.29, 7.31) among non-variant 339 carriers (t-test P=0.20) (Table 4). All 15 ADRB1 variant carriers had an 340 accelerometer-based sleep duration average of more than 6 hours (min=6 hours, 53 341 minutes). Similar observations were made when stratifying accelerometer data 342 analyses to weekend nights and weekday nights (**Supplementary Table 4**). 343 344 PER3, but not CRY2 or TIMELESS, variants are associated with advanced sleep 345 phase in the population-based cohorts, but with reduced effect size 346 Variants in five genes have previously been associated with familial advanced sleep 347 phase syndrome – characterised by approximately  $\geq 3$  hour shifts towards earlier 348 sleep and wake times. We previously tested the PER3 P415A/H417R variant in the 349 UK Biobank and found it was associated with self-report diurnal preference and 350 activity monitor derived sleep timing, although the size of the effect on sleep timing 351 (L5 time) was smaller than the initially published estimate of 4.2 hours (7.8 minutes, 352 95% CI: 4.2–13.2 minutes,  $P=4.3\times10^{-4}$ ). We confirmed this association using exome 353 sequence data and accelerometer data. The difference on average sleep-midpoint 354 timing between carriers and non-carriers based on exome-sequence data was 6.8 355 minutes (95% CI: 1.4-12.3 minutes, P=0.01) with a similar effect size for L5 timing

(Table 5). Variant carriers had an odds ratio of 1.36 (95% CI: 1.22 - 1.52, P=2×10<sup>-8</sup>) 356 357 for "definitely" being a morning person. We found no evidence that carriers of 358 previously reported pathogenic variants in the other two genes, CRY2 and 359 TIMELESS, had altered chronotype, L5 timing or sleep-midpoint indicative of earlier 360 sleep timing (Supplementary Tables 5-7). 361 362 CRY1 c.1657+3A>C is associated with diurnal preference and a delayed sleep 363 phase in a population-based cohort, but with reduced effect size CRY1 c.1657+3A>C has previously been associated with delayed sleep phase 364 365 disorder, characterised by an approximately 1-hour shift towards later sleep and wake times. In the UK Biobank, 10.1% and 11.1% of CRY1 heterozygous and 366 homozygous variant carriers, respectively, reported being "definitely an evening 367 368 person", compared to 7.9 % of non-variant carriers (Fisher's exact P=0.003) (Table 369 6). No carriers of the CRY1 variant reported being "definitely an evening person" in 370 the Finnish studies. The observed difference in the UK Biobank in sleep-midpoint 371 estimated from accelerometery for individuals with a CRY1 variant was 5.4 minutes 372 later (95% CI:-0.2,11.0, P=0.06), with a similar difference observed for L5 timing. 373 Similar point estimates were observed in our sensitivity analyses that included 374 restricting accelerometer data analyses to either weekend nights or weekday nights 375 (Supplementary Tables 8-10 and Supplementary Figs 1-3). 376 377 Heterozygous protein truncating variants in reported Mendelian sleep genes PER2 378 and PER3 are associated with sleep timing. 379 Most of the reported variants are missense variants and some, for example, CRY1 380 c.1657+3A>C have been shown to have a specific gain of function effect in *in-vitro* experiments<sup>10</sup>. Only the reported *TIMELESS* gene variant is a protein truncating 381 382 variant (PTV) and it is unclear whether the reported Mendelian sleep variants act through loss of function due to haploinsufficiency. We therefore identified all rare 383 384 (MAF<0.01%) nonsense, frameshift and essential splice site variants across the ten 385 Mendelian sleep and circadian genes. The number of individuals with rare high 386 confidence loss-of-function variants in these genes ranged from 10 for ADRB1 to 387 205 for *TIMELESS*. We subsequently performed burden testing of loss-of-function 388 variants for these 10 genes in up to 184.065 individuals of European ancestry. 389 including and adjusting for relatedness (**Supplementary Tables 11-14**). We 390 identified associations between PER2 and self-reported measures of diurnal 391 preference and accelerometer-estimates of sleep timing. We observed associations 392 between loss-of-function variants in the PER2 gene and UK Biobank participants 393 self-reporting as "definitely a morning person" (Burden  $P=4\times10^{-8}$ ) (**Supplementary** 394 **Table 12**), and accelerometer-estimates of sleep-midpoint (Burden  $P=5\times10^{-7}$ ) and L5 395 timing (Burden  $P=9\times10^{-4}$ )(Supplementary Table 14). Of 64 unrelated European carriers carrying at least one of the 50 loss-of-function variants in the PER2 gene, 396 397 58% (n=37) self-reported as "definitely a morning person" in contrast to 24% 398 (n=40,438) among non-carriers (Fisher's exact P<0.0001) (Supplementary Table 399 **15**). Within unrelated individuals, compared with non-carriers of loss-of-function 400 variants in PER2, carriers had an earlier average sleep-midpoint of ~57 minutes (t-401 test P<0.0001) (Supplementary Table 16) and an earlier average L5 timing of ~33 402 minutes (t-test *P*=0.027) (**Supplementary Table 17**). In addition, our burden testing 403 identified an association between loss-of-function variants in PER3 and L5-timing 404 (Burden  $P=4\times10^{-6}$ ) (Supplementary Table 14). Our gene-based analyses for high 405 confidence PTVs did not result in associations for other previously reported

406 monogenic genes for sleep duration or timing. We observed no associations in gene-407 based tests of rare missense variants in these genes after accounting for multiple 408 testing (Bonferroni P=0.0001 based on 42 tests across 10 genes).

409 410

### 411 **DISCUSSION**

412

413 Recent studies have identified 10 genes where specific variants are reported to 414 cause familial natural short sleep, familial advanced sleep phase, or delayed sleep 415 phase. These studies have tended to be based on a limited number of families 416 ascertained to have a specific sleep trait. This form of ascertainment means the 417 effect of the variants and genes when identified in the population is unknown. Here, 418 we show that most previously reported variants for Mendelian sleep and circadian 419 conditions are not highly penetrant when ascertained incidentally from the general 420 population. Incidental findings are becoming increasingly common with the increase 421 in whole genome sequencing both from direct-to-consumer companies and through 422 health services. It is important, therefore, to get accurate estimates of the risk of 423 developing a condition so that individuals are not misdiagnosed and/or potentially

- 424 incorrectly treated for a condition.
- 425

We and others have shown previously<sup>13</sup> that the penetrance of rare Mendelian 426 427 disease variants is likely to be lower when estimated from population-based cohorts 428 than in ascertained discovery or clinical cohorts and this may be the case for the 429 genes and variants reported here. It is also possible that some of the reported genes 430 and variants are not causes of the reported sleep conditions in humans. The 431 functional effect of each the variants assessed here are supported by extensive in 432 vitro and animal model studies. The level of human genetic evidence varies across 433 studies, from 6 individuals from a single pedigree for the ADBR1 variant to 78 434 individuals from 7 families for the CRY1 c.1657+3A>C variant. It is therefore possible 435 that some of the reported variants with weaker human genetic evidence do not 436 cause monogenic sleep and circadian conditions in humans. However, because of 437 the nature of the ascertainment, our study cannot address pathogenicity and can 438 only conclude that the effect of these variants when identified incidentally from the 439 population appears to be much weaker than previously reported. 440

441 There are several other possible explanations for the differences between our 442 studies. Genetic background may play a role. Sleep is so important to survival, that 443 homeostatic mechanisms are extremely robust. For example, the very strong circadian phenotype of homozygous PER2 KO allele<sup>27</sup> was completely absent when 444 crossed onto a C57/BI6 background<sup>28</sup>. Our work underscores the significant 445 446 challenges of behavioral genetics It is possible that an individual or family presenting 447 to a clinic with a specific sleep or circadian condition have an increased polygenic 448 susceptibility to sleep duration, in addition to the monogenic variant. For example, 449 we have recently identified 351 variants for being a morning person from genome-450 wide association studies. Individuals in the highest 5% of polygenic risk had an 451 average sleep timing of 25 mins earlier compared to the lowest polygenic risk 452 individuals. As has been shown for traits such as lipids and BMI<sup>29</sup>, this suggests that 453 extreme polygenic risk can have similar effect sizes to monogenic variants for sleep 454 traits. Ancestry differences may also play a role. For example, the CRY1 455 c.1657+3A>C association was discovered in an American family and followed up in

456 Turkish families. A recent paper has found association with the CRY1 variants and 457 sleep-midpoint timing (~40 mins) in an independent cohort of Turkish ancestry individuals<sup>30</sup>. The difference in effect size between these studies may be due to 458 459 different genetic backgrounds between these previous populations and the 460 predominantly Northern European ancestry population used in our analyses. There 461 are also potential environmental (e.g. daylight hours) and societal explanations for 462 the different results in this study compared to previous studies. 463 464 There are several limitations to our study which provide other possible explanations 465 for the weaker associations observed here compared to previous studies. First, the UK Biobank has a healthy volunteer bias<sup>31</sup> and may select against individuals with 466 467 sleep disorders. However, this is unlikely for FASP and FNSS where the phenotypes of phase advance or short sleep rarely affect individuals' well-being<sup>20</sup>. Additionally, 468 469 the allele frequency of the variants in UK Biobank is similar to that in a large 470 resource of exome data (gnomAD) suggesting limited selection against these 471 variants. Second, reported sleep patterns that are often shaped by social factors, 472 and thus may not reflect their underlying sleep preferences. This could explain the 473 lack of association with sleep timing for example. However, we find no association 474 with the variants with traits such as self-reported ease of getting up and limiting the 475 analyses to an individual's activity on the weekend shows a similar lack of 476 association. Additionally, we find no association with any measures of sleep quality 477 or disruption in the UK Biobank, including those defined by medical record codings, 478 although sleep fragmentation has been observed in CRY1 c.1657+3A>C carriers<sup>10</sup>. 479 480 Another limitation to this study is that it is not possible to do as detailed sleep and 481 circadian phenotyping in this large-scale study as is possible in smaller scale clinical 482 studies. We have, however, used multiple data sources including self-report and 483 activity monitor data and have used primary care and inpatient data to identify sleep disorders. We have previously validated the activity monitor sleep estimates against 484 polysomnography data<sup>32</sup> and it is a reliable measure of many sleep parameters. The 485 486 validity of the measures is also confirmed by the statistically robust associations with 487 PER2 and PER3 protein truncating variants using both self-report and 488 accelerometry, with effects of sleeping timing of approximately 1 hour. We have also 489 demonstrated this through the robust association of hundreds of common genetic variants with chronotype<sup>14</sup>, sleep duration<sup>33</sup> and other sleep measures through 490 genome-wide association studies (GWAS)<sup>19,21</sup>. The number of individuals with 491 492 variants is relatively low for some genes, but the number of individuals carrying 493 previously identified variants is usually larger than the number of available in the

494 original reports.

495 Our work demonstrates that haploinsufficiency of *PER2* affects circadian timing in humans. We find a substantial effect on chronotype and sleep timing for individuals 496 497 with heterozygous PER2 protein truncating variants. This is unexpected because 498 only homozygous Per2 knockout mice exhibit a circadian shortened circadian period, with no phenotype in heterozygotes<sup>34</sup>. The human genetic evidence for a role of the 499 PER2 S662G missense variant is robust with co-segregation in a large pedigree with 500 FASPS<sup>5</sup>. It was initially thought that the effect of this S662G variant was caused by 501 502 decreased phosphorylation of PER by CK1 that could stabilize it leading to PER 503 accumulating prematurely and shortened circadian period. Others have suggested

that the S662G mutation results in decreased PER2 levels and/or an increased 504

turnover of nuclear PER2<sup>35</sup>. Our work shows that, in humans, haploinsufficiency of 505

506 PER2 causes a substantial effect on diurnal preference and sleeping timing.

507 Our results indicate that most previously reported variants for Mendelian sleep and 508 circadian conditions are not highly penetrant causes of extreme sleep duration or 509 timing when ascertained incidentally from the population.

- 510
- 511

### 512 ACKNOWLEDGEMENTS

513

514 We thank Louis Ptáček, Alina Patke and Michael Young for helpful discussion and 515 comments on the manuscript. R.N.B is supported by grant MR/T00200X/1. Whole 516 genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) 517 program was supported by the National Heart, Lung and Blood Institute (NHLBI). 518 WGS for "NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA)" 519 (phs001416.v1.p1) was performed at the Broad Institute of MIT and Harvard 520 (3U54HG003067-13S1). Core support including centralized genomic read mapping 521 and genotype calling, along with variant guality metrics and filtering were provided by 522 the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract 523 HHSN268201800002I). Core support including phenotype harmonization, data 524 management, sample-identity QC, and general program coordination were provided 525 by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract 526 HHSN2682018000011). We gratefully acknowledge the studies and participants who 527 provided biological samples and data for MESA and TOPMed. JSK was supported 528 by the Pulmonary Fibrosis Foundation Scholars Award and grant K23-HL-150301 from the NHLBI. MRA was supported by grant K23-HL-150280, AJP was supported 529 530 by grant K23-HL-140199, and AM was supported by R01-HL131565 from the NHLBI. 531 EJB was supported by grant K23-AR-075112 from the National Institute of Arthritis 532 and Musculoskeletal and Skin Diseases. 533 534 The MESA project is conducted and supported by the National Heart, Lung, and 535 Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA 536 is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 537 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 538 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 539 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-540 95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-541 001079, and UL1-TR-001420. Also supported in part by the National Center for 542 Advancing Translational Sciences, CTSI grant UL1TR001881, and the National 543 Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center 544 (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research 545 Center. 546 547

# **ETHICS AND CONSENT**

548 The UK Biobank was granted ethical approval by the North West Multi-centre

549 Research Ethics Committee (MREC) to collect and distribute data and samples from

- 550 the participants (http://www.ukbiobank.ac.uk/ethics/) and covers the work in this
- 551 study, which was performed under UK Biobank application numbers 9072 and

- 552 16434. All participants included in these analyses gave informed consent to
- 553 participate.
- 554

### 555 DATA AVAILABILITY

- 556 The datasets analyzed for this study are available on application to the participating
- 557 studies.

## TABLES

| PubMed ID | d ID Gene Variant C |             | CHR:BP <sup>a</sup> | rsID <sup>b</sup> | Trait             | gnomAD AAF <sup>f</sup> | gnomAD EAF <sup>g</sup> |
|-----------|---------------------|-------------|---------------------|-------------------|-------------------|-------------------------|-------------------------|
| 33065013  | GRM1                | S458A       | 6:146352435         | rs151255685       | FNSS <sup>c</sup> | 2x10 <sup>-4</sup>      | 2x10 <sup>-4</sup>      |
| 33065013  | GRM1                | R889W       | 6:146426563         | rs768023437       | FNSS <sup>c</sup> | 3x10 <sup>-5</sup>      | 6x10 <sup>-5</sup>      |
| 31619542  | NPSR1               | Y206H       | 7:34827538          | rs1406844918      | FNSS <sup>c</sup> | 4x10 <sup>-6</sup>      | 9x10 <sup>-6</sup>      |
| 31473062  | ADRB1               | A187V       | 10:114044692        | rs776439595       | FNSS <sup>c</sup> | 4x10 <sup>-5</sup>      | 8x10 <sup>-5</sup>      |
| 19679812  | BHLHE41 (DEC2)      | P384R       | 12:26122364         | rs121912617       | FNSS <sup>c</sup> | 3x10 <sup>-5</sup>      | 5x10 <sup>-5</sup>      |
| 28388406  | CRY1                | c.1657+3A>C | 12:106992962        | rs184039278       | $DSPD^{d}$        | 4x10 <sup>-3</sup>      | 5x10 <sup>-3</sup>      |
| 26903630  | PER3                | P415A       | 1:7809893           | rs150812083       | FASP <sup>e</sup> | 6x10 <sup>-3</sup>      | 6x10 <sup>-3</sup>      |
| 26903630  | PER3                | H417R       | 1:7809900           | rs139315125       | FASP <sup>e</sup> | 6x10 <sup>-3</sup>      | 6x10 <sup>-3</sup>      |
| 11232563  | PER2                | PER2S662G   | 2:238257003         | rs121908635       | FASP <sup>e</sup> | -                       | -                       |
| 27529127  | CRY2                | A260T       | 11:45867648         | rs201220841       | FASP <sup>e</sup> | 6x10 <sup>-5</sup>      | 1x10 <sup>-4</sup>      |
| 31138685  | TIMELESS            | R1081X      | 12:56418347         | rs1465092391      | FASP <sup>e</sup> | 8x10 <sup>-6</sup>      | 2x10 <sup>-5</sup>      |
| 15800623  | CSNK1D              | T44A        | 17:82265743         | rs104894561       | FASP <sup>e</sup> | 4x10 <sup>-6</sup>      | 9x10 <sup>-6</sup>      |

**Table 1.** Summary of twelve variants previously reported to be causal for Mendelian sleep and circadian conditions, including the variant frequencies catalogued in gnomAD.

<sup>a</sup>chromosome and base-pair position defined by the Genome Reference Consortium Human Build 38; <sup>b</sup>reference SNP (rs) cluster identifier of variant; <sup>c</sup>familial natural short sleep; <sup>d</sup>delayed sleep phase disorder; <sup>e</sup>familial advanced sleep phase; <sup>f</sup>allele frequency of minor allele across all ancestries catalogued in gnomAD (version 2.1). <sup>g</sup>allele frequency of minor allele within samples of European ancestry (excluding Finnish) catalogued in gnomAD (version 2.1).

**Table 2.** Maximum genotype counts for 12 previously reported monogenic causes of sleep and circadian conditions in unrelated individuals of European ancestry from the UK Biobank, FinnGen and MESA studies. Genotype counts are based on availability of sleep characteristics relevant to each gene.

| •                             |                   |                      | UK Biobank           |                             |                      |                      | FINNGEN                     |                      | MESA                 |                             |                      |  |
|-------------------------------|-------------------|----------------------|----------------------|-----------------------------|----------------------|----------------------|-----------------------------|----------------------|----------------------|-----------------------------|----------------------|--|
| Gene / Variant                | Trait             | REF/ALT <sup>d</sup> | REF/REF <sup>e</sup> | <b>REF/ALT</b> <sup>†</sup> | ALT/ALT <sup>g</sup> | REF/REF <sup>e</sup> | <b>REF/ALT</b> <sup>†</sup> | ALT/ALT <sup>8</sup> | REF/REF <sup>e</sup> | <b>REF/ALT</b> <sup>†</sup> | ALT/ALT <sup>8</sup> |  |
| <i>GRM1 /</i> S458A           | FNSS <sup>a</sup> | T/G                  | 169,451              | 67                          | -                    | 5,927                | 2                           | 0                    | -                    | -                           | -                    |  |
| <i>GRM1  </i> R889W           | FNSS <sup>ª</sup> | A/T                  | 169,513              | 3                           | -                    | -                    | -                           | -                    | -                    | -                           | -                    |  |
| <i>NPSR1 /</i> Y206H          | FNSS <sup>ª</sup> | T/C                  | -                    | -                           | -                    | -                    | -                           | -                    | -                    | -                           | -                    |  |
| ADRB1 / A187V                 | FNSS <sup>a</sup> | C/T                  | 169,450              | 69                          | -                    | -                    | -                           | -                    | -                    | -                           | -                    |  |
| <i>BHLHE41 (DEC2)</i> / P384R | FNSS <sup>ª</sup> | G/C                  | 169,500              | 10                          | -                    | -                    | -                           | -                    | 1,993                | 22                          | -                    |  |
| <i>CRY1</i> / c.1657+3A>C     | $DSPD^{b}$        | T/G                  | 168,586              | 1,480                       | 9                    | 2,838                | 4                           | 0                    | -                    | -                           | -                    |  |
| <i>PER3 /</i> P415A           | FASP <sup>c</sup> | C/G                  | 168,500              | 1,565                       | 7                    | 2,734                | 149                         | 3                    | 2,003                | 12                          | -                    |  |
| <i>PER3  </i> H417R           | FASP <sup>c</sup> | A/G                  | 168,500              | 1,567                       | 7                    | 2,734                | 149                         | 3                    | 2,003                | 12                          | -                    |  |
| <i>PER2</i> / PER2S662G       | FASP <sup>c</sup> | A/G                  | -                    | -                           | -                    | -                    | -                           | -                    | -                    | -                           | -                    |  |
| <i>CRY2</i> / A260T           | FASP <sup>c</sup> | G/A                  | 170,038              | 38                          | -                    | -                    | -                           | -                    | -                    | -                           | -                    |  |
| TIMELESS / R1081X             | FASP <sup>c</sup> | G/A                  | 170,064              | 5                           | -                    | -                    | -                           | -                    | -                    | -                           | -                    |  |
| CSNK1D / T44A                 | FASP <sup>c</sup> | T/C                  | 170,075              | 1                           | -                    | -                    | -                           | -                    |                      | -                           | -                    |  |

<sup>a</sup>familial natural short sleep; <sup>b</sup>delayed sleep phase disorder; <sup>c</sup>familial advanced sleep phase; <sup>d</sup>reference allele / alternate allele; <sup>e</sup>number of homozygous carriers for reference allele; <sup>f</sup>number of heterozygous carriers; <sup>g</sup>number of homozygous carriers for alternate allele.

**Table 3.** Summary of self-reported sleep duration in UK Biobank (data field 1160) between carriers of variants previously reported to be causal for familial natural short sleep and non-carriers (homozygous reference called by UK Biobank exome-sequencing) who are also non-carriers for any of the other 12 variants described in this article.

|         |         |                      |         |          |                | Sel              | f-report         | sleep duratio           | n (hrs)        | Rep            | orting ≤6 hours slee | p                |
|---------|---------|----------------------|---------|----------|----------------|------------------|------------------|-------------------------|----------------|----------------|----------------------|------------------|
| Gene    | Variant | REF/ALT <sup>a</sup> | Study   | Genotype | N <sup>b</sup> | Min <sup>c</sup> | Max <sup>d</sup> | Mean (SD <sup>e</sup> ) | P <sup>f</sup> | % <sup>g</sup> | Cases / Controls     | $\mathbf{P}^{h}$ |
|         | A 107V  | c/T                  |         | c/c      | 166,291        | 1                | 12               | 7.17 (1.07)             | 0.00           | 23.74          | 39,484 / 126,807     | 1.00             |
| ADRBI A | A187V   | C/ I                 | UKB     | C/T      | 69             | 5                | 12               | 7.10 (1.03)             | 0.62           | 23.19          | 16 / 53              | 1.00             |
| рынел1  | 02040   | clc                  | סעוו    | G/G      | 166,283        | 1                | 12               | 7.17 (1.07)             | 0.60           | 23.74          | 39,483 / 126,800     | 0 47             |
| DHLHE41 | F 304N  | d, c                 | UND     | G/C      | 10             | 5                | 9                | 7.30 (1.06)             | 0.89           | 10.00          | 1/9                  | 0.47             |
|         |         | TIC                  | סעוו    | T/T      | 166,290        | 1                | 12               | 7.17 (1.07)             | 0.01           | 23.74          | 39,484 / 126,806     | 0.20             |
|         | C1E0A   |                      | UND     | T/G      | 67             | 4                | 10               | 7.13 (1.15)             | 0.81           | 28.36          | 19 / 48              | 0.59             |
| CDN11   | 34J6A   | 1/0                  | FinnCon | T/T      | 5,927          | 3                | 15               | 7.59 (1.20)             | 0.02           | 14.10          | 837 / 5,090          | 1 00             |
| GRIVII  |         |                      | FinnGen | T/G      | 2              | 7                | 8                | 7.50 (0.71)             | 0.92           | 0.00           | 0/2                  | 1.00             |
|         | A 00.0T | ۸/T                  | סעוו    | A/A      | 166,288        | 1                | 12               | 7.17 (1.07)             | 0.10           | 23.75          | 39,485 / 126,803     | 1 00             |
|         | A0091   | Ayı                  | UND     | A/T      | 3              | 8                | 8                | 8.00 (0.00)             | 0.18           | 0.00           | 0/3                  | 1.00             |

<sup>a</sup>reference allele / alternate allele; <sup>b</sup>number of individuals in genotype group; <sup>c</sup>minimum sleep duration self-reported in genotype group; <sup>d</sup>maximum sleep duration self-reported in genotype group; <sup>e</sup>standard deviation; <sup>f</sup>t-test *P*-value (two-sided); <sup>g</sup>%=percentage of individuals in genotype group self-reporting  $\leq$ 6 hours sleep duration (cases); <sup>h</sup>Fisher's exact-test *P*-value (two-sided).

**Table 4.** Summary of average accelerometer derived sleep duration (hours) (all nights) in the subset of exome-sequenced unrelated Europeans in UK Biobank, split by for carriers and non-carriers of variants previously reported to be causal for familial natural short sleep.

| Gene          | Variant          | Genotype | Nª     | Min <sup>b</sup> | Max   | Mean | SD <sup>d</sup> | P <sup>e</sup> |
|---------------|------------------|----------|--------|------------------|-------|------|-----------------|----------------|
|               | A 1 0 7\/        | c/c      | 34,168 | 1.63             | 11.87 | 7.30 | 0.86            | 0.20           |
| ADRBI         | A10/V            | C/T      | 15     | 6.89             | 8.83  | 7.59 | 0.49            | 0.20           |
|               | <i>C2)</i> P384R | G/G      | 34,167 | 1.63             | 11.87 | 7.30 | 0.86            | 0.02           |
| BHLHE4 (DEC2) |                  | G/C      | 4      | 6.26             | 8.25  | 7.51 | 0.92            | 0.62           |
|               | 64504            | т/т      | 34,166 | 1.63             | 11.87 | 7.30 | 0.86            | 0.02           |
| CDM1          | 5458A            | T/G      | 10     | 6.48             | 8.30  | 7.33 | 0.76            | 0.92           |
| GRIVII        | ABOOT            | A/A      | 34,167 | 1.63             | 11.87 | 7.30 | 0.86            |                |
|               | A8891            | A/T      | 0      | -                | -     | -    | -               | -              |

<sup>a</sup>number of individuals in genotype group; <sup>b</sup>minimum average sleep duration in genotype group; <sup>c</sup>maximum average sleep duration in genotype group; <sup>d</sup>standard deviation; <sup>e</sup>t-test *P*-value (two-sided).

**Table 5.** Proportion of individuals self-reporting as being "definitely a morning person", average L5 timing and average of sleepmidpoint across all nights for each genotype group of variants previously reported to be causal for familial advanced sleep phase in the UK Biobank (UKB), Finnish and MESA studies. Accelerometer-based estimates of sleep timing unavailable in the Finnish studies. Self-reported "Morningness" and accelerometer estimates of L5-timing unavailable in MESA.

|           |         | •       |          | Defin | itely a "Morning" P | erson  |                | Accele           | romete           | r L5 Tim | ing             |                | Accelerometer Sleep Midpoint Timing |                  |                  |       |                 |                    |  |
|-----------|---------|---------|----------|-------|---------------------|--------|----------------|------------------|------------------|----------|-----------------|----------------|-------------------------------------|------------------|------------------|-------|-----------------|--------------------|--|
| Gene      | Variant | Study   | Genotype | %ª    | Cases / Controls    | Pb     | N <sup>c</sup> | Min <sup>d</sup> | Max <sup>e</sup> | Mean     | SD <sup>f</sup> | P <sup>g</sup> | N <sup>c</sup>                      | Min <sup>d</sup> | Max <sup>e</sup> | Mean  | SD <sup>f</sup> | P <sup>g</sup>     |  |
|           |         |         | c/c      | 23.77 | 39,655 / 127,177    |        | 33,998         | 23.08            | 31.51            | 27.32    | 0.99            |                | 33,908                              | 23.37            | 30.59            | 27.01 | 0.85            |                    |  |
|           |         | UKB     | C/G      | 29.58 | 463 / 1,102         | <0.001 | 338            | 21.34            | 31.43            | 27.21    | 1.05            | 0.053          | 338                                 | 19.45            | 29.64            | 26.90 | 0.96            | 0.014 <sup>4</sup> |  |
|           |         |         | G/G      | 42.86 | 3 / 4               |        | 1              | 28.01            | 28.01            | 28.01    | -               |                | 1                                   | 27.60            | 27.60            | 27.60 | -               | nade               |  |
|           | D41EA   |         | c/c      | 22.4  | 613 / 2,121         |        | -              | -                | -                | -        | -               |                | -                                   | -                | -                | -     | -               | BAB 4              |  |
|           | P415A   | FinnGen | C/G      | 22.8  | 34 / 115            | 1.000  | -              | -                | -                | -        | -               | -              | -                                   | -                | -                | -     | -               | - abi              |  |
|           |         |         | G/G      | 0.00  | 0/3                 |        | -              | -                | -                | -        | -               |                | -                                   | -                | -                | -     | -               | e un               |  |
|           |         |         | c/c      | -     | -                   |        | -              | -                | -                | -        | -               |                | 1,925                               | 13.15            | 34.92            | 27.05 | 2.16            |                    |  |
| 05.02     |         | IVIESA  | C/G      | -     | -                   | -      | -              | -                | -                | -        | -               | -              | 10                                  | 26.12            | 27.98            | 26.96 | 0.67            | 0.900ª             |  |
| PER3      |         |         | A/A      | 23.77 | 39,655 / 127,177    |        | 33,997         | 23.08            | 31.51            | 27.32    | 0.99            |                | 33,907                              | 23.37            | 30.59            | 27.01 | 0.85            | Ρ                  |  |
|           |         | UKB     | A/G      | 29.55 | 463 / 1,104         | <0.001 | 339            | 21.34            | 31.43            | 27.21    | 1.05            | 0.06           | 339                                 | 19.45            | 29.64            | 26.90 | 0.96            | 0.018              |  |
|           |         |         | G/G      | 42.86 | 3 / 4               |        | 1              | 28.01            | 28.01            | 28.01    | -               |                | 1                                   | 27.60            | 27.60            | 27.60 | -               | <u>†</u>           |  |
|           |         |         | A/A      | 22.4  | 613 / 2,121         |        | -              | -                | -                | -        | -               |                | -                                   | _                | _                | _     | -               | nteri              |  |
|           | H417K   | FinnGen | A/G      | 22.8  | 34 / 115            | 1.000  | -              | -                | -                | -        | -               | -              | -                                   | -                | -                | -     | -               | - <del>natio</del> |  |
|           |         |         | G/G      | 0.00  | 0/3                 |        | -              | -                | -                | -        | -               |                | -                                   | -                | -                | -     | -               | nall               |  |
|           |         | MECA    | A/A      | -     | -                   |        | -              | -                | _                | -        | -               |                | 1,925                               | 13.15            | 34.92            | 27.05 | 2.16            | 0.000              |  |
|           |         | IVIESA  | A/G      | -     | -                   | -      | -              | -                | -                | -        | -               | -              | 10                                  | 26.12            | 27.98            | 26.96 | 0.67            | 0.9008             |  |
| 671/2     | ADCOT   |         | G/G      | 23.77 | 39,655 / 127,179    | 0.040  | 33,998         | 23.08            | 31.51            | 27.32    | 0.99            | 0.000          | 33,908                              | 23.37            | 30.59            | 27.01 | 0.85            | 0.040              |  |
| CRY2      | A260T   | ОКВ     | G/A      | 15.79 | 6 / 32              | 0.340  | 4              | 27.32            | 28.67            | 28.15    | 0.58            | 0.092          | 4                                   | 26.63            | 29.34            | 27.88 | 1.14            |                    |  |
| TINACLESS | D10041  |         | G/G      | 23.77 | 39,652 / 127,175    | 1 000  | 33,997         | 23.08            | 31.51            | 27.32    | 0.99            |                | 33,907                              | 23.37            | 30.59            | 27.01 | 0.85            |                    |  |
| TIMELESS  | R1081X  | UKB     | G/A      | 20.00 | 1/4                 | 1.000  | 0              | -                | -                | -        | -               | -              | -                                   | -                | -                | -     | -               |                    |  |

medRxiv preprint doi: https://doi.org/10.1101/2022.01.04.21268199; this version posted January 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

<sup>a</sup>percentage of individuals in genotype group self-reporting being "definitely a 'morning' person"; <sup>b</sup>Fisher's exact-test *P*-value (two-sided); <sup>c</sup>number of individuals; <sup>d</sup>minimum phenotypic value; <sup>e</sup>maximum phenotypic value; <sup>f</sup>SD=standard deviation; <sup>g</sup>carrier status t-test *P*-value (two-sided). Homozygous carriers for rare alleles combined with heterozygote carriers when performing Fisher's exact-test. **Table 6.** Proportion of individuals self-reporting as being "definitely an evening person", average L5 timing, and average sleepmidpoint across all nights for each genotype group of the *CRY1* variant previously reported to be causal for delayed sleep phase disorder in the UK Biobank (UKB), Finnish and MESA studies. Accelerometer based estimates of sleep timing unavailable in the Finnish studies. Self-reported "Eveningness" and accelerometer estimates of L5-timing unavailable in MESA.

|      |             |         |          | Defin | itely an "Evening" F | Accelerometer L5 Timing |                |                  |                  |       |      |                | Accelerometer Sleep Midpoint |                  |                  |       |                 |                |
|------|-------------|---------|----------|-------|----------------------|-------------------------|----------------|------------------|------------------|-------|------|----------------|------------------------------|------------------|------------------|-------|-----------------|----------------|
| Gene | Variant     | Study   | Genotype | %ª    | Cases/Controls       | Pb                      | N <sup>c</sup> | Min <sup>d</sup> | Max <sup>e</sup> | Mean  | SD   | P <sup>g</sup> | N <sup>c</sup>               | Min <sup>d</sup> | Max <sup>e</sup> | Mean  | SD <sup>f</sup> | P <sup>g</sup> |
|      |             |         | т/т      | 7.92  | 13,212 / 153,621     |                         | 33,998         | 23.08            | 31.51            | 27.32 | 0.99 |                | 33,908                       | 23.37            | 30.59            | 27.01 | 0.85            |                |
|      |             | UKB     | T/G      | 10.07 | 149 / 1,331          | 0.003                   | 318            | 24.06            | 30.38            | 27.41 | 1.00 | 0.132          | 318                          | 24.28            | 29.60            | 27.11 | 0.88            | 0.059          |
|      |             |         | G/G      | 11.11 | 1/8                  |                         | 4              | 25.08            | 28.44            | 26.50 | 1.48 |                | 4                            | 25.49            | 27.38            | 26.50 | 0.90            |                |
| CRY1 | c.1657+3A>C | F: 0    | т/т      | 10    | 284 / 2,554          | 1 000                   | -              | _                | -                | -     | -    |                | -                            | -                | -                | -     | -               |                |
|      |             | FinnGen | T/G      | 0     | 0/4                  | 1.000                   | -              | -                | -                | -     | -    | -              | -                            | -                | -                | -     | -               | -              |
|      |             |         | т/т      | -     | -                    |                         | -              | -                | -                | -     | -    |                | 1,914                        | 13.19            | 34.92            | 27.05 | 2.14            | 0 5 6 9        |
|      |             | IVIESA  | T/G      | -     | -                    | -                       | -              | -                | -                | -     | -    | -              | 21                           | 13.15            | 30.10            | 26.78 | 3.32            | 0.368          |

<sup>a</sup>percentage of individuals in genotype group self-reporting being "definitely a 'evening person"; <sup>b</sup>Fisher's exact-test *P*-value (two-sided); <sup>c</sup>number of individuals.; <sup>d</sup>minimum phenotypic value; <sup>e</sup>maximum phenotypic value; <sup>f</sup>standard deviation; <sup>g</sup>carrier status t-test *P*-value (two-sided). Homozygous carriers for rare alleles combined with heterozygote carriers when performing Fisher's exact-test.

# REFERENCES

1. Shi G, Xing L, Wu D, et al. A Rare Mutation of beta1-Adrenergic Receptor Affects Sleep/Wake Behaviors. *Neuron* 2019; **103**(6): 1044-55 e7.

2. Shi G, Yin C, Fan Z, et al. Mutations in Metabotropic Glutamate Receptor 1 Contribute to Natural Short Sleep Trait. *Curr Biol* 2020.

 Xing L, Shi G, Mostovoy Y, et al. Mutant neuropeptide S receptor reduces sleep duration with preserved memory consolidation. *Sci Transl Med* 2019; **11**(514).
 He Y, Jones CR, Fujiki N, et al. The transcriptional repressor DEC2 regulates sleep length in mammals. *Science* 2009; **325**(5942): 866-70.

5. Toh KL, Jones CR, He Y, et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. *Science* 2001; **291**(5506): 1040-3.

6. Zhang L, Hirano A, Hsu PK, et al. A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait. *Proc Natl Acad Sci U S A* 2016; **113**(11): E1536-44.

7. Hirano A, Shi G, Jones CR, et al. A Cryptochrome 2 mutation yields advanced sleep phase in humans. *Elife* 2016; **5**.

8. Xu Y, Padiath QS, Shapiro RE, et al. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. *Nature* 2005; **434**(7033): 640-4.

9. Kurien P, Hsu PK, Leon J, et al. TIMELESS mutation alters phase responsiveness and causes advanced sleep phase. *Proc Natl Acad Sci U S A* 2019; **116**(24): 12045-53.

10. Patke A, Murphy PJ, Onat OE, et al. Mutation of the Human Circadian Clock Gene CRY1 in Familial Delayed Sleep Phase Disorder. *Cell* 2017; **169**(2): 203-15 e13.

11. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; **12**(3): e1001779.

12. Tuke MA, Ruth KS, Wood AR, et al. Mosaic Turner syndrome shows reduced penetrance in an adult population study. *Genet Med* 2019; **21**(4): 877-86.

13. Wright CF, West B, Tuke M, et al. Assessing the Pathogenicity, Penetrance, and Expressivity of Putative Disease-Causing Variants in a Population Setting. *Am J Hum Genet* 2019; **104**(2): 275-86.

14. Jones SE, Lane JM, Wood AR, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. *Nat Commun* 2019; **10**(1): 343.

15. Weedon MN, Jackson L, Harrison JW, et al. Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation. *BMJ* 2021; **372**: n214.

16. Weedon MN, Jackson L, Harrison JW, et al. Assessing the analytical validity of SNP-chips for detecting very rare pathogenic variants: implications for direct-to-consumer genetic testing. *bioRxiv, doi: 101101/696799* 2019.

17. Szustakowski JD, Balasubramanian S, Kvikstad E, et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. *Nat Genet* 2021; **53**(7): 942-8.

18. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. *Nat Biotechnol* 2011; **29**(1): 24-6.

19. Lane JM, Jones SE, Dashti HS, et al. Biological and clinical insights from genetics of insomnia symptoms. *Nat Genet* 2019; **51**(3): 387-93.

20. Ashbrook LH, Krystal AD, Fu YH, Ptacek LJ. Genetics of the human circadian clock and sleep homeostat. *Neuropsychopharmacology* 2020; **45**(1): 45-54.

21. Pulit SL, Stoneman C, Morris AP, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* 2019; **28**(1): 166-74.

22. Borodulin K, Tolonen H, Jousilahti P, et al. Cohort Profile: The National FINRISK Study. *Int J Epidemiol* 2018; **47**(3): 696-i.

23. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. *Am J Epidemiol* 2002; **156**(9): 871-81.

24. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. *Genome Biol* 2016; **17**(1): 122.

25. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 2020; **581**(7809): 434-43.

26. Mbatchou J, Barnard L, Backman J, et al. Computationally efficient whole genome regression for quantitative and binary traits. *BioRxiv* 2021.

27. Bae K, Jin X, Maywood ES, Hastings MH, Reppert SM, Weaver DR. Differential functions of mPer1, mPer2, and mPer3 in the SCN circadian clock. *Neuron* 2001; **30**(2): 525-36.

28. Xu Y, Toh KL, Jones CR, Shin JY, Fu YH, Ptacek LJ. Modeling of a human circadian mutation yields insights into clock regulation by PER2. *Cell* 2007; **128**(1): 59-70.

29. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet* 2018; **50**(9): 1219-24.

30. Smieszek SP, Brzezynski JL, Kaden AR, et al. An Observational Study Investigating the CRY1Δ11 Variant Associated with Delayed Sleep-wake Patterns and Circadian Metabolic Output. *PREPRINT Research Square, DOI: 1021203/rs3rs-468649/v1* 2021.

31. Munafo MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection bias can substantially influence observed associations. *Int J Epidemiol* 2018; **47**(1): 226-35.

32. van Hees VT, Sabia S, Jones SE, et al. Estimating sleep parameters using an accelerometer without sleep diary. *Sci Rep* 2018; **8**(1): 12975.

33. Dashti HS, Jones SE, Wood AR, et al. Genome-wide association study identifies genetic loci for self-reported habitual sleep duration supported by accelerometer-derived estimates. *Nat Commun* 2019; **10**(1): 1100.

34. Zheng B, Larkin DW, Albrecht U, et al. The mPer2 gene encodes a functional component of the mammalian circadian clock. *Nature* 1999; **400**(6740): 169-73.

35. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. *Nat Rev Genet* 2008; **9**(10): 764-75.